Mapi Pharma News Today

The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition multiple sclerosis...

Health news and commentary from around the Web gathered by <em>MedPage Today</em> staff

The AI fever that took hold of investors in the past few months is showing some signs of easing. Investors are wondering if things are going a bit too fast, which led to some sell-offs in iconic... -March 11, 2024 at 09:38 am EDT - MarketScreener

GA Depot 40mg is a long-acting version

The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable form of GA.

Israeli company Mapi could receive milestone payments from Viatris worth tens of millions of dollars, and royalties from sales, if the product ever reaches the market.

Multiple sclerosis and pulmonary arterial hypertension are disease states expected to have new medications in the upcoming year

/PRNewswire/ -- DelveInsights Spinal Cord Injury Market Insights report includes a comprehensive understanding of current treatment practices, spinal cord...

The products include Indomethacin 50 mg suppositories, Fluocinolone Acetonide Oil 0.01%, GA Depot 40 mg, Saxagliptin Tablets, 2.5 mg and 5 mg

/PRNewswire/ -- The multiple sclerosis market size in US is expected to increase by USD 3.95 billion from 2021 to 2026, with a CAGR of 5.83% according to the...